See also:
What is the most important information I should know about Tadact?
5 mg Film-coated Tablet: Hypersensitivity to the active substance or to any of the excipients.
In clinical studies, Tadact was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and Tadact on the nitric oxide/cGMP pathway. Therefore, administration of Tadact to patients who are using any form of organic nitrate is contraindicated..
Tadact, must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease.
20 mg Film-coated Tablet: Nitrates and Tadact must not be used concomitantly. Co-administration of Tadact with nitric oxide donors, organic nitrates or organic nitrites in any form either regularly or intermittently is contraindicated. Drugs which must not be used concomitantly include, but are not limited to, glyceryl trinitrate (injection, tablets, sprays or patches), isosorbide salts, sodium nitroprusside, amyl nitrite, nicorandil or organic nitrates in any form. In clinical studies, Tadact was shown to potentiate the hypotensive effects of both acute and chronic nitrate administration. This is thought to result from the combined effects of nitrates and Tadact on the nitric oxide/cGMP pathway.
Based on the results of a clinical study in which 150 subjects receiving daily doses of Tadact 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various times, this interaction lasted for more than 24 hours and was no longer detectable when 48 hours had elapsed after the last Tadact dose. Thus, in a patient prescribed Tadact, where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should have elapsed after the last dose of Tadact before nitrate administration is considered. In such circumstances, nitrates should only be administered under close medical supervision with appropriate haemodynamic monitoring.
5 mg and 20 mg Film-coated Tablet: The following groups of patients with cardiovascular disease were not included in clinical trials and the use of Tadact is therefore contraindicated: Patients with myocardial infarction within the last 90 days; patients with unstable angina or angina occurring during sexual intercourse; patients with New York Heart Association Class 2 or greater heart failure in the last 6 months; patients with uncontrolled arrhythmias, hypotension (<90/50 mm Hg), or uncontrolled hypertension; patients with a stroke within the last 6 months.
Tadact is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure.
Tadact should not be used in patients with a known hypersensitivity to Tadact or to any ingredient of the tablet.
See also:
What are the possible side effects of Tadact?
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Tadact was administered to over 9000 men during clinical trials worldwide. In trials of Tadact for once daily use, a total of 1434, 905, and 115 were treated for at least 6 months, 1 year, and 2 years, respectively. For Tadact for use as needed, over 1300 and 1000 subjects were treated for at least 6 months and 1 year, respectively.
Tadact For Use As Needed For EDIn eight primary placebo-controlled clinical studies of 12 weeks duration, mean age was 59 years (range 22 to 88) and the discontinuation rate due to adverse events in patients treated with Tadact 10 or 20 mg was 3.1%, compared to 1.4% in placebo treated patients.
When taken as recommended in the placebo-controlled clinical trials, the following adverse reactions were reported for Tadact for use as needed:
Table 1: Treatment-Emergent Adverse Reactions Reported by ≥ 2% of Patients Treated with Tadact (10 or 20 mg) and More Frequent on Drug than Placebo in the Eight Primary Placebo- Controlled Clinical Studies (Including a Study in Patients with Diabetes ) for Tadact for Us e as Needed for ED
| Adverse Reaction | Placebo (N=476) | Tadact 5 mg (N=151) | Tadact 10 mg (N=394) | Tadact 20 mg (N=635) |
| Headache | 5% | 11% | 11% | 15% |
| Dyspepsia | 1% | 4% | 8% | 10% |
| Back pain | 3% | 3% | 5% | 6% |
| Myalgia | 1% | 1% | 4% | 3% |
| Nasal congestion | 1% | 2% | 3% | 3% |
| FlushingThe term flushing includes: facial flushing and flushing |
In three placebo-controlled clinical trials of 12 or 24 weeks duration, mean age was 58 years (range 21 to 82) and the discontinuation rate due to adverse events in patients treated with Tadact was 4.1%, compared to 2.8% in placebo-treated patients.
The following adverse reactions were reported in clinical trials of 12 weeks duration:
Table 2: Treatment-Emergent Adverse Reactions Reported by ≥ 2% of Patients Treated with Tadact for Once Daily Us e (2.5 or 5 mg) and More Frequent on Drug than Placebo in the Three Primary Placebo-Controlled Phase 3 Studies of 12 weeks Treatment Duration (Including a Study in Patients with Diabetes ) for Tadact for Once Daily Us e for ED
| Adverse Reaction | Placebo (N=248) | Tadact 2.5 mg (N=196) | Tadact 5 mg (N=304) |
| Headache | 5% | 3% | 6% |
| Dyspepsia | 2% | 4% | 5% |
| Naso pharyngitis | 4% | 4% | 3% |
| Back pain | 1% | 3% | 3% |
| Upper respiratory tract infection | 1% | 3% | 3% |
| Flushing | 1% | 1% | 3% |
| Myalgia | 1% | 2% | 2% |
| Cough | 0% | 4% | 2% |
| Diarrhea | 0% | 1% | 2% |
| Nasal congestion | 0% | 2% | 2% |
| Pain in extremity | 0% | 1% | 2% |
| Urinary tract infection | 0% | 2% | 0% |
| Gastroesophageal reflux disease | 0% | 2% | 1% |
| Abdominal pain | 0% | 2% | 1% |
The following adverse reactions were reported over 24 weeks treatment duration in one placebo-controlled clinical study:
Table 3: Treatment-Emergent Adverse Reactions Reported by ≥ 2% of Patients Treated with Tadact for Once Daily Us e (2.5 or 5 mg) and More Frequent on Drug than Placebo in One Placebo-Controlled Clinical Study of 24 Weeks Treatment Duration for Tadact for Once Daily Use for ED
| Adverse Reaction | Placebo (N=94) | Tadact 2.5 mg (N=96) | Tadact 5 mg (N=97) |
| Naso pharyngitis | 5% | 6% | 6% |
| Gastroenteritis | 2% | 3% | 5% |
| Back pain | 3% | 5% | 2% |
| Upper respiratory tract infection | 0% | 3% | 4% |
| Dyspepsia | 1% | 4% | 1% |
| Gastroesophageal reflux disease | 0% | 3% | 2% |
| Myalgia | 2% | 4% | 1% |
| Hypertension | 0% | 1% | 3% |
| Nasal congestion | 0% | 0% | 4% |
In three placebo-controlled clinical trials of 12 weeks duration, two in patients with BPH and one in patients with ED and BPH, the mean age was 63 years (range 44 to 93) and the discontinuation rate due to adverse events in patients treated with Tadact was 3.6% compared to 1.6% in placebo-treated patients. Adverse reactions leading to discontinuation reported by at least 2 patients treated with Tadact included headache, upper abdominal pain, and myalgia. The following adverse reactions were reported.
Table 4: Treatment-Emergent Adverse Reactions Reported by ≥ 1% of Patients Treated with Tadact for Once Daily Use (5 mg) and More Frequent on Drug than Placebo in Three Placebo- Controlled Clinical Studies of 12 Weeks Treatment Duration, including Two Studies for Tadact for Once Daily Us e for BPH and One Study for ED and BPH
| Adverse Reaction | Placebo (N=576) | Tadact 5 mg (N=581) |
| Headache | 2.3% | 4.1% |
| Dyspepsia | 0.2% | 2.4% |
| Back pain | 1.4% | 2.4% |
| Naso pharyngitis | 1.6% | 2.1% |
| Diarrhea | 1.0% | 1.4% |
| Pain in extremity | 0.0% | 1.4% |
| Myalgia | 0.3% | 1.2% |
| Dizziness | 0.5% | 1.0% |
Additional, less frequent adverse reactions ( < 1%) reported in the controlled clinical trials of Tadact for BPH or ED and BPH included: gastroesophageal reflux disease, upper abdominal pain, nausea, vomiting, arthralgia, and muscle spasm.
Back pain or myalgia was reported at incidence rates described in Tables 1 through 4. In Tadact clinical pharmacology trials, back pain or myalgia generally occurred 12 to 24 hours after dosing and typically resolved within 48 hours. The back pain/myalgia associated with Tadact treatment was characterized by diffuse bilateral lower lumbar, gluteal, thigh, or thoracolumbar muscular discomfort and was exacerbated by recumbency. In general, pain was reported as mild or moderate in severity and resolved without medical treatment, but severe back pain was reported with a low frequency ( < 5% of all reports). When medical treatment was necessary, acetaminophen or non-steroidal anti-inflammatory drugs were generally effective; however, in a small percentage of subjects who required treatment, a mild narcotic (e.g., codeine) was used. Overall, approximately 0.5% of all subjects treated with Tadact for on demand use discontinued treatment as a consequence of back pain/myalgia. In the 1-year open label extension study, back pain and myalgia were reported in 5.5% and 1.3% of patients, respectively. Diagnostic testing, including measures for inflammation, muscle injury, or renal damage revealed no evidence of medically significant underlying pathology. Incidence rates for Tadact for once daily use for ED, BPH and BPH/ED are described in Tables 2, 3 and 4. In studies of Tadact for once daily use, adverse reactions of back pain and myalgia were generally mild or moderate with a discontinuation rate of < 1% across all indications.
Across placebo-controlled studies with Tadact for use as needed for ED, diarrhea was reported more frequently in patients 65 years of age and older who were treated with Tadact (2.5% of patients).
Across all studies with any Tadact dose, reports of changes in color vision were rare ( < 0.1% of patients).
The following section identifies additional, less frequent events ( < 2%) reported in controlled clinical trials of Tadact for once daily use or use as needed. A causal relationship of these events to Tadact is uncertain. Excluded from this list are those events that were minor, those with no plausible relation to drug use, and reports too imprecise to be meaningful:
Body as a Whole - asthenia, face edema, fatigue, pain, peripheral edema
Cardiovascular - angina pectoris, chest pain, hypotension, myocardial infarction, postural hypotension, palpitations, syncope, tachycardia
Digestive - abnormal liver function tests, dry mouth, dysphagia, esophagitis, gastritis, GGTP increased, loose stools, nausea, upper abdominal pain, vomiting, gastroesophageal reflux disease, hemorrhoidal hemorrhage, rectal hemorrhage
Musculoskeletal - arthralgia, neck pain
Nervous - dizziness, hypesthesia, insomnia, paresthesia, somnolence, vertigo Renal and Urinary
Tadact tablets are indicated for the treatment of erectile dysfunction (ED).
Benign Prostatic Hyperplasia
Tadact tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
Erectile Dysfunction and Benign Prostatic Hyperplasia
Tadact tablets are indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH).
Limitation of Use
If Tadact tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of Tadact tablets decrease from 4 weeks until 26 weeks, and the incremental benefit of Tadact tablets beyond 26 weeks is unknown.
Tadact is used to treat men who have erectile dysfunction (also called sexual impotence). Tadact belongs to a group of medicines called phosphodiesterase 5 (PDE5) inhibitors. These medicines prevent an enzyme called phosphodiesterase type-5 from working too quickly. The penis is one of the areas where this enzyme works.
Erectile dysfunction is a condition where the penis does not harden and expand when a man is sexually excited, or when he cannot keep an erection. When a man is sexually stimulated, his body's normal response is to increase blood flow to his penis to produce an erection. By controlling the enzyme, Tadact helps to maintain an erection after the penis is stroked by increasing blood flow to the penis. Without physical action to the penis, such as that occurring during sexual intercourse, Tadact will not work to cause an erection.
Tadact is also used to treat men who have signs and symptoms of benign prostatic hyperplasia (BPH). BPH is caused by an enlarged prostate. Men with BPH usually have difficulty urinating, a decreased flow of urination, hesitation at the beginning of urination, and a need to get up at night to urinate. Tadact will make these symptoms less severe and reduce the chance that prostate surgery will be needed. Tadact is also used to treat erectile dysfunction and signs and symptoms of BPH.
Tadact is also used in both men and women to treat the symptoms of pulmonary arterial hypertension. This is high blood pressure that occurs in the main artery that carries blood from the right side of the heart (the ventricle) to the lungs. When the smaller blood vessels in the lungs become more resistant to blood flow, the right ventricle must work harder to pump enough blood through the lungs. Tadact works on the PDE5 enzyme in the lungs to relax the blood vessels. This will increase the supply of blood to the lungs and reduce the workload of the heart.
Tadact is available only with your doctor's prescription..
Tadact is an orally adminstered drug used to treat male erectile dysfunction (impotence). It is marketed worldwide under the brand name Tadact. It is a phosphodiesterase 5 (PDE5) inhibitor. Tadact's distinguishing pharmacologic feature is its longer half-life (17.5 hours) compared with Viagra and Levitra (4-5 hours). This longer half-life results in a longer duration of action and is, in part, responsible for the Tadact nickname of the "weekend pill." This longer half-life also is the basis of current investigation for Tadact's use in pulmonary arterial hypertension as a once-daily therapy. [Wikipedia]
Use Tadact as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Tadact.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Tadact is used to treat high blood pressure in the lungs (pulmonary hypertension). It works by relaxing and widening the blood vessels in your lungs which allows the blood to flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise.
OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.
Tadact is also available in another brand for treating erectile dysfunction-ED in men. It may also be used to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH).
How to use TadactRead the Patient Information Leaflet provided by your pharmacist before you start taking Tadact and each time you get a refill. If you have any questions, ask your doctor or pharmacist.
To treat high blood pressure in the lungs, take this medication by mouth as directed by your doctor, with or without food, usually once daily.
The dosage is based on your medical condition, response to treatment, and other medications you may be taking. Be sure to tell your doctor and pharmacist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).
Take this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day.
Tell your doctor if your condition does not improve or if it worsens.
Do not split Tadact tablets; entire dose should be taken.
Tadact for Use as Needed for Erectile Dysfunction
The recommended dose of Tadact for once daily use is 5 mg, taken at approximately the same time every day, without regard to timing of sexual activity.
Use with Food
Tadact may be taken without regard to food.
Use in Specific Populations
Renal Impairment
Tadact for Use as Needed
Tadact for Once Daily Use
Erectile Dysfunction
Benign Prostatic Hyperplasia and Erectile Dysfunction/Benign Prostatic Hyperplasia
Hepatic Impairment
Tadact for Use as Needed
Tadact for Once Daily Use
Nitrates
Concomitant use of nitrates in any form is contraindicated.
Alpha-Blockers
ED — When Tadact is coadministered with an alpha-blocker in patients being treated for ED, patients should be stable on alpha-blocker therapy prior to initiating treatment, and Tadact should be initiated at the lowest recommended dose.
BPH — Tadact is not recommended for use in combination with alpha-blockers for the treatment of BPH.
CYP3A4 Inhibitors
Tadact for Use as Needed — For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose of Tadact is 10 mg, not to exceed once every 72 hours.
Tadact for Once Daily Use — For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose is 2.5 mg.
See also:
What other drugs will affect Tadact?
Administration of Tadact to patients who are using any form of organic nitrate, is contraindicated. In clinical pharmacology studies, Tadact was shown to potentiate the hypotensive effect of nitrates. In a patient who has taken Tadact, where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should elapse after the last dose of Tadact before nitrate administration is considered. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring.
Alpha-BlockersCaution is advised when PDE5 inhibitors are coadministered with alpha-blockers. PDE5 inhibitors, including Tadact, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. Clinical pharmacology studies have been conducted with coadministration of Tadact with doxazosin, tamsulosin or alfuzosin..
AntihypertensivesPDE5 inhibitors, including Tadact, are mild systemic vasodilators. Clinical pharmacology studies were conducted to assess the effect of Tadact on the potentiation of the bloodpressure- lowering effects of selected antihypertensive medications (amlodipine, angiotensin II receptor blockers, bendrofluazide, enalapril, and metoprolol). Small reductions in blood pressure occurred following coadministration of Tadact with these agents compared with placebo..
AlcoholBoth alcohol and Tadact, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood-pressure-lowering effects of each individual compound may be increased. Substantial consumption of alcohol (e.g., 5 units or greater) in combination with Tadact can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Tadact did not affect alcohol plasma concentrations and alcohol did not affect Tadact plasma concentrations..
Potential For Other Drugs To Affect Tadact.
AntacidsSimultaneous administration of an antacid (magnesium hydroxide/aluminum hydroxide) and Tadact reduced the apparent rate of absorption of Tadact without altering exposure (AUC) to Tadact.
H2 Antagonists (e.g. Nizatidine)An increase in gastric pH resulting from administration of nizatidine had no significant effect on pharmacokinetics.
Cytochrome P450 InhibitorsTadact is a substrate of and predominantly metabolized by CYP3A4. Studies have shown that drugs that inhibit CYP3A4 can increase Tadact exposure.
CYP3A4 (e.g., Ketoconazole)
Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4, increased Tadact 20 mg single-dose exposure (AUC) by 312% and Cmax by 22%, relative to the values for Tadact 20 mg alone. Ketoconazole (200 mg daily) increased Tadact 10-mg singledose exposure (AUC) by 107% and Cmax by 15%, relative to the values for Tadact 10 mg alone.
Although specific interactions have not been studied, other CYP3A4 inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase Tadact exposure.
HIV Protease inhibitorRitonavir (500 mg or 600 mg twice daily at steady state), an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased Tadact 20-mg single-dose exposure (AUC) by 32% with a 30% reduction in Cmax, relative to the values for Tadact 20 mg alone. Ritonavir (200 mg twice daily), increased Tadact 20-mg single-dose exposure (AUC) by 124% with no change in Cmax, relative to the values for Tadact 20 mg alone. Although specific interactions have not been studied, other HIV protease inhibitors would likely increase Tadact exposure.
Cytochrome P450 InducersStudies have shown that drugs that induce CYP3A4 can decrease Tadact exposure.
CYP3A4 (e.g., Rifampin)
